News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alvine Pharmaceuticals, Inc. ALV003 Receives Fast Track Designation From the FDA for the Potential Treatment of Celiac Disease


9/5/2012 9:32:28 AM

SAN CARLOS, Calif.--(BUSINESS WIRE)--Alvine Pharmaceuticals, Inc., a leader in celiac disease therapeutics development, announced today that its lead candidate, ALV003, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of patients with celiac disease. Alvine is currently conducting phase 2 clinical trials with ALV003.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES